Straits Times Index
3,290.70 +24.75 (+0.76%) Nikkei
38,229.11 +155.13 (+0.41%) Hang Seng
18,963.68 +425.87 (+2.30%) FTSE 100
8,441.08 +59.73 (+0.71%) Bitcoin USD
62,945.16 +2,037.29 (+3.34%) CMC Crypto 200
1,303.77 -54.23 (-3.99%)
Recursion Pharmaceuticals, Inc. (RXRX)
Pre-market:
- Zacks
Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Tops Revenue Estimates
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of 9.30% and 3.29%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results
On track to read out multiple Phase 2 clinical trials in the coming quarters, beginning in Q3 2024Performance benchmarking completed on BioHive-2, Recursion's next generation supercomputer, which will support the construction of foundation models across biology, chemistry, and patient outcomesTranscriptomics technology has continued to be scaled to more than 1 million transcriptomes with a whole-genome knockout transcriptomics map to be completed in the coming quartersEntered into a multi-year a
- Zacks
Recursion Pharmaceuticals (RXRX) Increases Yet Falls Behind Market: What Investors Need to Know
In the closing of the recent trading day, Recursion Pharmaceuticals (RXRX) stood at $8.84, denoting a +0.57% change from the preceding trading day.
